ScholarIQanswers from OpenAlex

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

PaperCitations, authors & open-access status

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer have?

ScholarIQcitation count

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer has 3,565 citations in the OpenAlex counts ScholarIQ stores.

When was First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer published?

ScholarIQyear

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer has 2018 year in the ScholarIQ index.

What is the open-access status of First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer?

ScholarIQoa status

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer has bronze oa status in the ScholarIQ index.

What is the DOI of First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer?

ScholarIQdoi

The DOI for First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer is on the source record.

What is the PMID of First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer?

ScholarIQpmid

The PMID for First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer is on the source record.

What is the OpenAlex record for First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer?

ScholarIQopenalex

The OpenAlex for First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial